Search Results

You are looking at 41 - 50 of 1,101 items for :

  • "breast cancer" x
  • All content x
Clear All
Full access

Sharon H. Giordano, Anthony D. Elias, and William J. Gradishar

Panel Refines Important Breast Cancer Recommendations In the absence of substantive changes to the NCCN Guidelines for Breast Cancer this year, members of the NCCN panel discussed refinements to the recommendations, described the use of

Full access

Jason P. Wilson, David Mattson, and Stephen B. Edge

A lthough the involvement of axillary nodes remains a significant prognostic factor used in the management of breast cancer, the management of the axilla has changed dramatically. Among women with clinically negative nodes, the National Surgical

Full access

Tomas G. Lyons and Mark E. Robson

. Evolution of PARP Targeting in Breast Cancer There are currently a number of PARPi in clinical development, including olaparib, veliparib, niraparib, rucaparib, and talazoparib. These PARPi are similar in that they all inhibit PARP1 and PARP2 catalytic

Full access

Aki Morikawa and Andrew D. Seidman

Contemporary systemic therapy is commonly informed by the classification of breast cancer based solely on hormonal receptor and HER2 status. Triple-negative is a category of exclusion defined by immunohistochemical and/or fluorescence in situ

Full access

Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee

Background Over the last several decades, breast cancer mortality in the United States has declined substantially. 1 , 2 This decrease has been attributed in part to screening mammography and its ability to detect localized asymptomatic breast

Full access

Stefanie S. Jeffrey, Per Eystein Lønning, and Bruce E. Hillner

– 424 . 4 Yarden Y Baselga J Miles D . Molecular approach to breast cancer treatment . Semin Oncol 2004 ; 31 ( suppl 10 ): 6 – 13 . 5 Perou CM Jeffrey SS van de Rijn M . Distinctive gene expression patterns in human mammary

Full access

Constance D. Lehman, Wendy DeMartini, Benjamin O. Anderson, and Stephen B. Edge

Edited by Kerrin G. Robinson

. Radiographics 1993 ; 13 : 905 – 912 . 4 Orel SG Schnall MD Powell CM . Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy . Radiology 1995 ; 196 : 115 – 122 . 5 Mumtaz H Hall-Craggs MA Davidson T . Staging

Full access

Kathryn J. Ruddy, Lindsey Sangaralingham, Rachel A. Freedman, Sarah S. Mougalian, Heather Neuman, Caprice Greenberg, Ahmedin Jemal, Narjust Duma, Tufia C. Haddad, Valerie Lemaine, Karthik Ghosh, Tina J. Hieken, Katie Hunt, Celine Vachon, Cary P. Gross, and Nilay D. Shah

Breast cancer survivors who have residual breast tissue are recommended to undergo mammographic surveillance annually. ASCO, the American Cancer Society (ACS), and NCCN recommend annual mammograms beginning at 1 year after the mammogram that led

Full access

Presenters: Melinda L. Telli and William J. Gradishar

Patients with HER2-positive breast cancer can now benefit from 4 newly approved agents shown to increase time to progression and, in some cases, overall survival (OS), as described at the NCCN 2021 Virtual Annual Conference by Melinda L. Telli, MD

Full access

Akriti Gupta Jain, Abdul Kareem Khan, Ranjeet Kumar, Mohammed Wazir, Syed Askari Hasan, and Umair Majeed

Background: Breast Cancer (BC) is common, with 1 in 8 U.S. women (12.4%) developing invasive breast cancer in their lifetime. BC is associated with the most awareness campaigns with pink ribbon as its symbol. October was earmarked as the breast